In the absence of blind luck in stumbling upon a successful vaccine for HIV/AIDS, scientists will probably need to resolve a number of specific scientific obstacles in order to create a sufficient knowledge-base for informed vaccine design. The proposed studies are directed at delineating the targets of the strain-specific neutralizing antibody responses that follow HIV-1 infection and at achieving a better understanding of the strategies employed by HIV to resist neutralization by antibodies so that this information can be harnessed for improved immunogen design. Monkeys infected with SHIV-KB9 make antibodies that neutralize SHIV- KB9 but not SHIV-DH12. Conversely, monkeys infected with SHIV-DH12 make antibodies that neutralize SHIV-DH12 but not SHIV-KB9. This situation exactly paralells natural human infection with HIV-1 where the neutralizing response 3-10 months after infection is highly strain-specific. While it is reasonable to think that the variable loops of gp120 are principally responsible for this strain specificity, this has not been formally demonstrated. Furthermore, which variable loop or loops are the predominant determinant and whether they serve principally as the direct target of antibody recognition have not been elucidated. We will generate reagents and perform analyses that will allow precise delineation of the predominant determinants of the strain-specific neutralizing antibody response. These will include: variable loop swaps using SHIV-KB9 and SHIV-DH12;variable loop swaps using envelope genes from primary HIV-1 human infection;analysis of ability of these recombinant viruses to be neutralized by sequential serum samples from SHIV-KB9- and SHIV-DH12-infected monkeys and from the same HIV-1-infected people that will be the source of the envelope genes;analysis of the recognition sequences of neutralizing monoclonal Fabs from phage-display derived from the same sources. In addition to these studies, the extent to which certain N-linked carbohydrates shield CD4-binding.domain regions and CCRS-binding domain regions on gp120 to limit the neutralizing antibody response to more conserved determinants will be analyzed. Finally, a potential role for O-linked carbohydrates in shielding antibody access will be investigated. Results from these studies have the potential to enlighten immunogen design for the elicitation of neutralizing antibodies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI025328-23
Application #
7784457
Study Section
AIDS Immunology and Pathogenesis Study Section (AIP)
Program Officer
Sharma, Opendra K
Project Start
1987-09-01
Project End
2012-03-31
Budget Start
2010-04-01
Budget End
2012-03-31
Support Year
23
Fiscal Year
2010
Total Cost
$398,429
Indirect Cost
Name
Harvard University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
02115
Termini, James M; Church, Elizabeth S; Silver, Zachary A et al. (2017) Human Immunodeficiency Virus and Simian Immunodeficiency Virus Maintain High Levels of Infectivity in the Complete Absence of Mucin-Type O-Glycosylation. J Virol 91:
Stansell, Elizabeth; Panico, Maria; Canis, Kevin et al. (2015) Gp120 on HIV-1 Virions Lacks O-Linked Carbohydrate. PLoS One 10:e0124784
Postler, Thomas S; Bixby, Jacqueline G; Desrosiers, Ronald C et al. (2014) Systematic analysis of intracellular trafficking motifs located within the cytoplasmic domain of simian immunodeficiency virus glycoprotein gp41. PLoS One 9:e114753
Westmoreland, Susan V; Converse, A Peter; Hrecka, Kasia et al. (2014) SIV vpx is essential for macrophage infection but not for development of AIDS. PLoS One 9:e84463
Postler, Thomas S; Desrosiers, Ronald C (2012) The cytoplasmic domain of the HIV-1 glycoprotein gp41 induces NF-?B activation through TGF-?-activated kinase 1. Cell Host Microbe 11:181-93
Postler, Thomas S; Martinez-Navio, José M; Yuste, Eloísa et al. (2012) Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein. J Virol 86:1145-57
Martinez-Navio, Jose M; Desrosiers, Ronald C (2012) Neutralizing capacity of monoclonal antibodies that recognize peptide sequences underlying the carbohydrates on gp41 of simian immunodeficiency virus. J Virol 86:12484-93
Stansell, Elizabeth; Canis, Kevin; Haslam, Stuart M et al. (2011) Simian immunodeficiency virus from the sooty mangabey and rhesus macaque is modified with O-linked carbohydrate. J Virol 85:582-95
Stansell, Elizabeth; Desrosiers, Ronald C (2010) Fundamental difference in the content of high-mannose carbohydrate in the HIV-1 and HIV-2 lineages. J Virol 84:8998-9009
Sato, Shuji; Yuste, Eloisa; Lauer, William A et al. (2008) Potent antibody-mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo. J Virol 82:9739-52

Showing the most recent 10 out of 79 publications